Conclusion
A comparative study of the fasting and postprandial plasma pharmacokinetics of nifedipine extended-release tablets demonstrated the bioequivalence of nifedipine extended-release tablets (Hunan Dino Pharmaceutical Co., Ltd.) and the reference formulation, nifedipine controlled-release tablets (trade name: Baysinto®, size: 30 mg/tablet Bayer AG). Both drugs had a good safety profile, with no serious adverse reactions occurring throughout the study period. Notably, the high-fat diet reduced the AUC curve area by approximately 4.8%, with little change in Cmax but an almost twofold advance in Tmax.